Cyclacel Pharmaceuticals, Inc., based in Kuala Lumpur, Malaysia, has announced that a stockholder holding a majority of the company's voting power has taken action by written consent. This decision involves 12,164,301 shares of common stock, representing approximately 51.2% of the total voting power. The action, taken on June 18, 2025, allows the company to proceed with certain corporate matters without the need for a special meeting of stockholders. Cyclacel Pharmaceuticals continues its commitment to advancing its corporate objectives with this strategic move.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.